Azimuth Capital Management’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | $4.77M | Buy |
35,982
+1,423
| +4% | +$171K | 0.2% | 154 |
|
|
2021
Q4 | $4.03M | Sell |
34,559
-285
| -0.8% | -$33.5K | 0.16% | 163 |
|
|
2021
Q3 | $4.18M | Buy |
34,844
+390
| +1% | +$45.4K | 0.18% | 158 |
|
|
2021
Q2 | $4.13M | Buy |
34,454
+1,905
| +6% | +$209K | 0.18% | 165 |
|
|
2021
Q1 | $3.24M | Buy |
32,549
+1,987
| +7% | +$200K | 0.15% | 179 |
|
|
2020
Q4 | $3.06M | Buy |
30,562
+1,450
| +5% | +$154K | 0.15% | 172 |
|
|
2020
Q3 | $3.19M | Buy |
29,112
+175
| +0.6% | +$19.5K | 0.19% | 143 |
|
|
2020
Q2 | $3.06M | Sell |
28,937
-402
| -1% | -$41.5K | 0.19% | 136 |
|
|
2020
Q1 | $2.62M | Sell |
29,339
-70
| -0.2% | -$6.59K | 0.2% | 136 |
|
|
2019
Q4 | $2.93M | Sell |
29,409
-82
| -0.3% | -$7.72K | 0.18% | 157 |
|
|
2019
Q3 | $2.63M | Buy |
29,491
+410
| +1% | +$35.5K | 0.17% | 158 |
|
|
2019
Q2 | $2.4M | Sell |
29,081
-68
| -0.2% | -$5.33K | 0.16% | 163 |
|
|
2019
Q1 | $2.36M | Sell |
29,149
-17,323
| -37% | -$1.37M | 0.16% | 162 |
|
|
2018
Q4 | $3.53M | Sell |
46,472
-417
| -0.9% | -$32.6K | 0.27% | 120 |
|
|
2018
Q3 | $3.71M | Sell |
46,889
-2,175
| -4% | -$165K | 0.25% | 126 |
|
|
2018
Q2 | $3.44M | Sell |
49,064
-1,794
| -4% | -$129K | 0.25% | 133 |
|
|
2018
Q1 | $3.56M | Sell |
50,858
-5,000
| -9% | -$346K | 0.26% | 132 |
|
|
2017
Q4 | $3.88M | Buy |
55,858
+3,198
| +6% | +$216K | 0.28% | 128 |
|
|
2017
Q3 | $3.57M | Buy |
52,660
+2,275
| +5% | +$144K | 0.27% | 131 |
|
|
2017
Q2 | $3.44M | Buy |
50,385
+1,140
| +2% | +$74.4K | 0.27% | 127 |
|
|
2017
Q1 | $3.07M | Buy |
49,245
+2,291
| +5% | +$133K | 0.25% | 141 |
|
|
2016
Q4 | $2.57M | Sell |
46,954
-1,915
| -4% | -$109K | 0.22% | 148 |
|
|
2016
Q3 | $3.21M | Buy |
48,869
+385
| +0.8% | +$25.2K | 0.28% | 117 |
|
|
2016
Q2 | $2.93M | Buy |
48,484
+2,170
| +5% | +$126K | 0.26% | 126 |
|
|
2016
Q1 | $2.61M | Buy |
46,314
+2,212
| +5% | +$133K | 0.25% | 128 |
|
|
2015
Q4 | $2.99M | Buy |
44,102
+2,750
| +7% | +$180K | 0.29% | 119 |
|
|
2015
Q3 | $2.63M | Sell |
41,352
-3,392
| -8% | -$223K | 0.28% | 123 |
|
|
2015
Q2 | $2.85M | Buy |
44,744
+900
| +2% | +$61.6K | 0.28% | 123 |
|
|
2015
Q1 | $3M | Buy |
43,844
+19,202
| +78% | +$1.33M | 0.29% | 114 |
|
|
2014
Q4 | $1.73M | Buy |
24,642
+2,285
| +10% | +$164K | 0.18% | 156 |
|
|
2014
Q3 | $1.6M | Buy |
22,357
+1,600
| +8% | +$117K | 0.18% | 158 |
|
|
2014
Q2 | $1.54M | Buy |
20,757
+1,043
| +5% | +$75.4K | 0.17% | 159 |
|
|
2014
Q1 | $1.28M | Buy |
19,714
+259
| +1% | +$16.7K | 0.15% | 163 |
|
|
2013
Q4 | $1.16M | Buy |
+19,455
| New | +$1.06M | 0.14% | 161 |
|
Other funds holding AZN
Azimuth Capital Management's AZN Position: Q1 2022 in Review
Azimuth Capital Management increased its AstraZeneca (AZN) stake by 4.1% in Q1 2022, buying an estimated $171K and bringing the position to 35,982 shares worth $4.77M. The position accounts for 0.2% of the portfolio, ranked #154.
Azimuth Capital Management first reported a position in AZN in Q4 2013 and has held it in 34 quarters since. 981 funds tracked by Wall St. Rank hold AZN as of Q1 2022.
- Azimuth Capital Management held 35,982 shares of AstraZeneca worth $4.77M as of Q1 2022.
- Azimuth Capital Management bought 1,423 AstraZeneca shares in Q1 2022, an estimated $171K.
- AstraZeneca made up 0.2% of Azimuth Capital Management's portfolio in Q1 2022, its #154 holding.
- Azimuth Capital Management first reported a position in AstraZeneca in Q4 2013 and has held it in 34 quarters since.
- 981 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2022.
Based on Azimuth Capital Management's 13F filing for Q1 2022, filed 13 May 2022.